RIGL – Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

RIGL

$18.29

Name : Rigel Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $326,886,208.00

EPSttm : 2.09

Rigel Pharmaceuticals, Inc.

$18.29

1.72%

$0.32

Float Short %

10.65

Margin Of Safety %

Put/Call OI Ratio

0.24

EPS Next Q Diff

-0.33

EPS Last/This Y

1.6

EPS This/Next Y

-0.6

Price

18.29

Target Price

35.89

Analyst Recom

2.2

Performance Q

-12.24

Relative Volume

0.85

Beta

1.29

Ticker: RIGL

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	RIGL	17.19	0.35	0.00	1030
2025-04-15	RIGL	17.06	0.33	0.60	1052
2025-04-16	RIGL	16.46	0.33	0.00	1064
2025-04-17	RIGL	16.81	0.30	0.03	1039
2025-04-18	RIGL	16.85	0.30	0.03	1039
2025-04-21	RIGL	16.89	0.21	0.30	882
2025-04-22	RIGL	17.72	0.21	0.45	913
2025-04-23	RIGL	18.17	0.22	0.20	927
2025-04-24	RIGL	19.01	0.21	0.19	966
2025-04-25	RIGL	19.28	0.20738974970203	0.34210526315789	1013
2025-04-28	RIGL	19.41	0.21678321678322	0.18181818181818	1044
2025-04-29	RIGL	19.61	0.21	0.00	1092
2025-04-30	RIGL	19.55	0.21	0.17	1098
2025-05-01	RIGL	18.69	0.21	0.14	1111
2025-05-02	RIGL	19.36	0.20	0.86	1137
2025-05-05	RIGL	19.15	0.21	0.10	1149
2025-05-06	RIGL	18.29	0.20	2.50	1218
2025-05-07	RIGL	18.47	0.24	0.25	1269
2025-05-08	RIGL	18.87	0.26	0.16	1304
2025-05-09	RIGL	18.79	0.23	0.80	1376
2025-05-12	RIGL	18.59	0.24	0.16	1386
2025-05-13	RIGL	18.29	0.24	0.39	1401
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	RIGL	17.21	117.9	0.3	1.24
2025-04-15	RIGL	17.04	117.9	-0.8	1.24
2025-04-16	RIGL	16.47	117.9	-1.4	1.24
2025-04-17	RIGL	16.85	117.9	0.1	1.24
2025-04-18	RIGL	16.85	117.9	-0.5	1.24
2025-04-21	RIGL	16.90	117.9	-0.4	1.24
2025-04-22	RIGL	17.74	117.9	0.8	1.24
2025-04-23	RIGL	18.16	117.9	0.1	1.24
2025-04-24	RIGL	19.07	117.9	0.9	1.24
2025-04-25	RIGL	19.28	117.9	-0.2	1.24
2025-04-28	RIGL	19.41	117.9	-0.3	1.24
2025-04-29	RIGL	19.57	117.9	-0.3	1.24
2025-04-30	RIGL	19.56	117.9	-0.5	1.24
2025-05-01	RIGL	18.72	117.9	-1.6	1.24
2025-05-02	RIGL	19.36	117.9	0.4	1.24
2025-05-05	RIGL	19.11	117.9	-0.9	1.24
2025-05-06	RIGL	18.24	117.9	-1.7	1.24
2025-05-07	RIGL	18.47	117.9	-0.2	1.24
2025-05-08	RIGL	18.87	117.9	0.1	1.24
2025-05-09	RIGL	18.77	117.9	52.4	2.59
2025-05-12	RIGL	18.61	117.9	52.3	2.59
2025-05-13	RIGL	18.29	3144.5	31.8	2.59
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	RIGL	-3.94	2.64	10.39
2025-04-15	RIGL	-3.94	2.64	10.39
2025-04-16	RIGL	-3.93	2.64	10.39
2025-04-17	RIGL	-3.93	2.64	10.39
2025-04-18	RIGL	-3.93	2.64	10.39
2025-04-21	RIGL	-3.93	4.04	10.39
2025-04-22	RIGL	-3.93	4.04	10.39
2025-04-23	RIGL	-3.93	4.04	10.39
2025-04-24	RIGL	-3.93	4.04	10.39
2025-04-25	RIGL	-3.93	4.04	10.39
2025-04-28	RIGL	-3.93	-1.38	10.72
2025-04-29	RIGL	-3.93	-1.38	10.72
2025-04-30	RIGL	-3.93	-1.38	10.72
2025-05-01	RIGL	-3.93	-1.38	10.72
2025-05-02	RIGL	-3.93	-1.38	10.72
2025-05-05	RIGL	-3.93	-2.70	10.72
2025-05-06	RIGL	-3.93	-2.70	10.72
2025-05-07	RIGL	-3.93	-2.70	10.72
2025-05-08	RIGL	-3.93	-2.70	10.72
2025-05-09	RIGL	-3.93	-2.70	10.71
2025-05-12	RIGL	-3.93	1.03	10.65
2025-05-13	RIGL	-3.93	1.03	10.65
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

0.63

Avg. EPS Est. Current Quarter

1.83

Avg. EPS Est. Next Quarter

0.3

Insider Transactions

-3.93

Institutional Transactions

1.03

Beta

1.29

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

26.97

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

66.8

Max Drawdown 5-Year %

-86.4

Target Price

35.89

P/E

8.83

Forward P/E

9.22

PEG

0.25

P/S

1.61

P/B

17.6

P/Free Cash Flow

9.2

EPS

2.07

Average EPS Est. Cur. Y

2.59

EPS Next Y. (Est.)

1.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

18.31

Relative Volume

0.85

Return on Equity vs Sector %

176.6

Return on Equity vs Industry %

193.5

EPS 1 7Days Diff

1.3

EPS 1 30Days Diff

1.34

EBIT Estimation

31.8

Rigel Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 162

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

stock quote shares RIGL – Rigel Pharmaceuticals, Inc. Stock Price stock today

news today RIGL – Rigel Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RIGL – Rigel Pharmaceuticals, Inc. yahoo finance google finance

stock history RIGL – Rigel Pharmaceuticals, Inc. invest stock market

stock prices RIGL premarket after hours

ticker RIGL fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

RIGL – Rigel Pharmaceuticals, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RIGL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y